Pilot of Osanetant to Reduce Severity of Hot Flashes in Men With Adenocarcinoma of the Prostate (POSH-MAP)
Latest Information Update: 27 Feb 2024
At a glance
- Drugs Osanetant (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms POSH-MAP
- 19 Feb 2024 Planned End Date changed from 1 Nov 2025 to 5 Oct 2023.
- 19 Feb 2024 Planned primary completion date changed from 1 Nov 2024 to 22 Sep 2023.
- 19 Feb 2024 Planned initiation date changed from 1 Jan 2023 to 3 Jan 2023.